Brian M Slomovitz1, Yunyun Jiang1, Melinda S Yates1, Pamela T Soliman1, Taren Johnston1, Maureen Nowakowski1, Charles Levenback1, Qian Zhang1, Kari Ring1, Mark F Munsell1, David M Gershenson1, Karen H Lu1, Robert L Coleman2. 1. Brian M. Slomovitz, Yunyun Jiang, Melinda S. Yates, Pamela T. Soliman, Taren Johnston, Charles Levenback, Qian Zhang, Kari Ring, Mark F. Munsell, David M. Gershenson, Karen H. Lu, and Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian M. Slomovitz and Maureen Nowakowski, Morristown Medical Center, Morristown, NJ; and Brian M. Slomovitz, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL. 2. Brian M. Slomovitz, Yunyun Jiang, Melinda S. Yates, Pamela T. Soliman, Taren Johnston, Charles Levenback, Qian Zhang, Kari Ring, Mark F. Munsell, David M. Gershenson, Karen H. Lu, and Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian M. Slomovitz and Maureen Nowakowski, Morristown Medical Center, Morristown, NJ; and Brian M. Slomovitz, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL. rcoleman@mdanderson.org.
Abstract
PURPOSE: The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. PATIENTS AND METHODS: Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response. RESULTS: Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. CONCLUSION: Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.
PURPOSE: The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. PATIENTS AND METHODS: Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response. RESULTS: Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. CONCLUSION:Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.
Authors: José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Gini F Fleming; Virginia L Filiaci; Brandon Marzullo; Richard J Zaino; Susan A Davidson; Michael Pearl; Vicky Makker; James J Burke; Susan L Zweizig; Linda Van Le; Parviz Hanjani; Gordon Downey; Joan L Walker; Henry D Reyes; Kimberly K Leslie Journal: Gynecol Oncol Date: 2014-01-20 Impact factor: 5.482
Authors: Brian M Slomovitz; Karen H Lu; Taren Johnston; Robert L Coleman; Mark Munsell; Russell R Broaddus; Cheryl Walker; Lois M Ramondetta; Thomas W Burke; David M Gershenson; Judith Wolf Journal: Cancer Date: 2010-08-02 Impact factor: 6.860
Authors: Steven C Plaxe; John A Blessing; Nader Husseinzadeh; Kenneth D Webster; Janet S Rader; Charles J Dunton Journal: Gynecol Oncol Date: 2002-02 Impact factor: 5.482
Authors: Carol Aghajanian; Michael W Sill; Kathleen M Darcy; Benjamin Greer; D Scott McMeekin; Peter G Rose; Jacob Rotmensch; Mack N Barnes; Parviz Hanjani; Kimberly K Leslie Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Teruaki Fujishita; Koji Aoki; Heidi A Lane; Masahiro Aoki; Makoto M Taketo Journal: Proc Natl Acad Sci U S A Date: 2008-09-03 Impact factor: 11.205
Authors: Janelle B Pakish; Qian Zhang; Zhongyuan Chen; Han Liang; Gary B Chisholm; Ying Yuan; Samuel C Mok; Russell R Broaddus; Karen H Lu; Melinda S Yates Journal: Clin Cancer Res Date: 2017-03-06 Impact factor: 12.531
Authors: Kari L Ring; Melinda S Yates; Rosemarie Schmandt; Michaela Onstad; Qian Zhang; Joseph Celestino; Suet-Ying Kwan; Karen H Lu Journal: Int J Gynecol Cancer Date: 2017-06 Impact factor: 3.437
Authors: Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall Journal: CA Cancer J Clin Date: 2019-05-22 Impact factor: 508.702
Authors: Vicky Makker; Fernando O Recio; Ling Ma; Ursula A Matulonis; Jennifer O Lauchle; Hema Parmar; Houston N Gilbert; Joseph A Ware; Rui Zhu; Shan Lu; Ling-Yuh Huw; Yulei Wang; Hartmut Koeppen; Jill M Spoerke; Mark R Lackner; Carol A Aghajanian Journal: Cancer Date: 2016-09-07 Impact factor: 6.860
Authors: Ramez N Eskander; Shamshad Ali; Thanh Dellinger; Heather A Lankes; Leslie M Randall; Nilsa C Ramirez; Bradley J Monk; Joan L Walker; Eric Eisenhauer; Bang H Hoang Journal: Int J Gynecol Cancer Date: 2016-01 Impact factor: 3.437
Authors: Andrea P Myers; Virginia L Filiaci; Yuping Zhang; Michael Pearl; Kian Behbakht; Vicky Makker; Parviz Hanjani; Susan Zweizig; James J Burke; Gordon Downey; Kimberly K Leslie; Paul Van Hummelen; Michael J Birrer; Gini F Fleming Journal: Gynecol Oncol Date: 2016-04 Impact factor: 5.482
Authors: Lorna Rodriguez-Rodriguez; Kim M Hirshfield; Veronica Rojas; Robert S DiPaola; Darlene Gibbon; Mira Hellmann; Sara Isani; Aliza Leiser; Gregory M Riedlinger; Allison Wagreich; Siraj M Ali; Julia A Elvin; Vincent A Miller; Shridar Ganesan Journal: Gynecol Oncol Date: 2016-04 Impact factor: 5.482
Authors: Muhammad R Khawaja; Alpa M Nick; Vinu Madhusudanannair; Siqing Fu; David Hong; Lacey M McQuinn; Chaan S Ng; Sarina A Piha-Paul; Filip Janku; Vivek Subbiah; Apostolia Tsimberidou; Daniel Karp; Funda Meric-Bernstam; Karen H Lu; Aung Naing Journal: Cancer Chemother Pharmacol Date: 2016-03-24 Impact factor: 3.333
Authors: Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810